Program of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicenter, randomized controlled study (PRIZE) sub study
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Febuxostat (Primary)
- Indications Hyperuricaemia
- Focus Pharmacodynamics
- Acronyms PRIZE sub study
- 25 Aug 2022 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 30 Apr 2021 to 31 Dec 2021.
- 12 Aug 2020 New trial record